Cargando…
Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis
The core pathogenic process in the common marmoset model of multiple sclerosis (MS) is the activation of memory-like T cells specific for peptide 34 to 56 derived from the extracellular domain of myelin/oligodendrocyte glycoprotein (MOG(34-56)). Immunization with MOG(34-56) in incomplete Freund’s ad...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280389/ https://www.ncbi.nlm.nih.gov/pubmed/22012268 http://dx.doi.org/10.1007/s11481-011-9320-5 |
_version_ | 1782223824091086848 |
---|---|
author | Jagessar, S. Anwar Gran, Bruno Heijmans, Nicole Bauer, Jan Laman, Jon D. ‘t Hart, Bert A. Constantinescu, Cris S. |
author_facet | Jagessar, S. Anwar Gran, Bruno Heijmans, Nicole Bauer, Jan Laman, Jon D. ‘t Hart, Bert A. Constantinescu, Cris S. |
author_sort | Jagessar, S. Anwar |
collection | PubMed |
description | The core pathogenic process in the common marmoset model of multiple sclerosis (MS) is the activation of memory-like T cells specific for peptide 34 to 56 derived from the extracellular domain of myelin/oligodendrocyte glycoprotein (MOG(34-56)). Immunization with MOG(34-56) in incomplete Freund’s adjuvant is a sufficient stimulus for in vivo activation of these T cells, together with the induction of MS-like disease and CNS pathology. Ex vivo functional characteristics of MOG(34-56) specific T cells are specific cytolysis of peptide pulsed target cells and high IL-17A production. To indentify possible functions in this new model of T helper 1 cells, which play a central pathogenic role in MS models induced with complete Freund’s adjuvant, we tested the effect of human interferon-γ (IFNγ) administration during disease initiation of the disease (day 0–25) and around the time of disease expression (psd 56–81). The results show a clear modulatory effect of early IFNγ treatment on humoral and cellular autoimmune parameters, but no generalized mitigating effect on the disease course. These results argue against a prominent pathogenic role of T helper 1 cells in this new marmoset EAE model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11481-011-9320-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3280389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-32803892012-03-01 Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis Jagessar, S. Anwar Gran, Bruno Heijmans, Nicole Bauer, Jan Laman, Jon D. ‘t Hart, Bert A. Constantinescu, Cris S. J Neuroimmune Pharmacol Original Article The core pathogenic process in the common marmoset model of multiple sclerosis (MS) is the activation of memory-like T cells specific for peptide 34 to 56 derived from the extracellular domain of myelin/oligodendrocyte glycoprotein (MOG(34-56)). Immunization with MOG(34-56) in incomplete Freund’s adjuvant is a sufficient stimulus for in vivo activation of these T cells, together with the induction of MS-like disease and CNS pathology. Ex vivo functional characteristics of MOG(34-56) specific T cells are specific cytolysis of peptide pulsed target cells and high IL-17A production. To indentify possible functions in this new model of T helper 1 cells, which play a central pathogenic role in MS models induced with complete Freund’s adjuvant, we tested the effect of human interferon-γ (IFNγ) administration during disease initiation of the disease (day 0–25) and around the time of disease expression (psd 56–81). The results show a clear modulatory effect of early IFNγ treatment on humoral and cellular autoimmune parameters, but no generalized mitigating effect on the disease course. These results argue against a prominent pathogenic role of T helper 1 cells in this new marmoset EAE model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11481-011-9320-5) contains supplementary material, which is available to authorized users. Springer US 2011-10-20 2012 /pmc/articles/PMC3280389/ /pubmed/22012268 http://dx.doi.org/10.1007/s11481-011-9320-5 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Article Jagessar, S. Anwar Gran, Bruno Heijmans, Nicole Bauer, Jan Laman, Jon D. ‘t Hart, Bert A. Constantinescu, Cris S. Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis |
title | Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis |
title_full | Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis |
title_fullStr | Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis |
title_full_unstemmed | Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis |
title_short | Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis |
title_sort | discrepant effects of human interferon-gamma on clinical and immunological disease parameters in a novel marmoset model for multiple sclerosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280389/ https://www.ncbi.nlm.nih.gov/pubmed/22012268 http://dx.doi.org/10.1007/s11481-011-9320-5 |
work_keys_str_mv | AT jagessarsanwar discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis AT granbruno discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis AT heijmansnicole discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis AT bauerjan discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis AT lamanjond discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis AT thartberta discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis AT constantinescucriss discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis |